Hikal Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI Listing Regulations'.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Limited has received a warning letter from the US FDA for its Jigani, Bengaluru manufacturing facility, dated August 20, 2025. This follows an inspection carried out by the US FDA at the facility from February 3 to February 7, 2025, about which the company had previously informed the exchanges on February 8 and May 23, 2025. A warning letter from the US FDA indicates that the regulator has identified significant deviations from good manufacturing practice (cGMP) standards that need to be addressed. The company has stated it is committed to working closely with the US FDA to resolve the issues and uphold cGMP quality standards across all its facilities.
A US FDA warning letter is a serious regulatory action that could restrict approvals or supplies from the Jigani facility to the US market, potentially affecting revenue from that unit. The stock may face short-term negative pressure, though the extent of impact will depend on how quickly the company resolves the issues with the FDA.